AI-Powered Portfolio Management in Pharmaceuticals: The Complete Strategic, Financial, and IP Intelligence Guide
Executive Summary The pharmaceutical industry runs on a contradiction that has defined the last 25 years. The science has never […]
The Complete Expert Guide to FDA Orange Book and Purple Book Patent Research: IP Strategy, Exclusivity Mechanics, and Market Entry Intelligence
1. Why Patent Database Literacy Is a Competitive Asset Patent information does not merely describe a drug’s legal status. It
Computational Drug Repurposing: The Complete IP, Technology, and Investment Guide
Drug repurposing has moved well past the era of accidental bedside observations. Today, systematic computational platforms screen millions of compound-indication
Computational Drug Repurposing: The Complete IP, Technology, and Investment Guide Read Post »
PBM Power Map: How Pharmacy Benefit Managers Control Drug Pricing, Formulary Access, and the $700 Billion Prescription Drug Market
Who actually controls what a drug costs at the pharmacy counter? It is not the manufacturer who sets the list
The Pharma Procurement Drain: A Technical Audit of the Mistakes Costing the Industry Billions
Executive Summary Pharmaceutical procurement costs at the average U.S. hospital nearly doubled between 2014 and 2021, climbing from $10.21 million
Drug Patent Intelligence for Out-Licensing: The Definitive Playbook for Pharma BD Teams
The difference between a licensing deal that captures peak asset value and one that leaves money on the table often
Drug Patent Intelligence for Out-Licensing: The Definitive Playbook for Pharma BD Teams Read Post »
Quantitative Methods for Drug Portfolio Optimization: The Complete Technical Guide for Pharma IP Teams, R&D Leads, and Institutional Investors
1. The Economics of Pharmaceutical Portfolio Failure Why Portfolio Optimization Is Not Optional Pharmaceutical R&D is among the most capital-intensive
Pharmaceutical Patent Due Diligence in M&A: The Definitive Analyst’s Guide to IP Valuation, Risk Quantification, and Deal Architecture
Part I: The Strategic Logic of Patent Due Diligence Why Pharma IP Is the Business, Not Just an Asset In
Patent Box Tax Strategy for Pharma: The Complete IP & Investment Playbook
Every blockbuster drug carries two distinct asset classes: the molecule itself and the legal monopoly wrapped around it. The Patent
Patent Box Tax Strategy for Pharma: The Complete IP & Investment Playbook Read Post »
